The FDA has told Shire to produce more information about its experimental attention deficit disorder drug SHP 465. The company said in a statement Thursday that the request will push back its plans for resubmitting the drug.
Shire expects to submit the drug for an adult indication and says it is working with the FDA to hammer out clinical trial needs.
